Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing
Authors:
- 10 September 2018
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 144 (11) , 2167-2175
Abstract
Purpose Analysis of circulating tumor DNA (ctDNA) offers an unbiased and noninvasive way to assess the genetic profiles of tumors. This study aimed to analyze mutations in ctDNA and their correlation with tissue mutations in patients with a variety of cancers. Methods We included 21 cancer patients treated with surgical resection for whom we collected paired tissue and plasma samples. Next-generation sequencing (NGS) of all exons was performed in a targeted human comprehensive cancer panel consisting of 275 genes. Results Six patients had at least one mutation that was concordant between tissue and ctDNA sequencing. Among all mutations (n = 35) detected by tissue and blood sequencing, 20% (n = 7) were concordant at the gene level. Tissue and ctDNA sequencing identified driver mutations in 66.67% and 47.62% of the tested samples, respectively. Tissue and ctDNA NGS detected actionable alterations in 57.14% and 33.33% of patients, respectively. When somatic alterations identified by each test were combined, the total proportion of patients with actionable mutations increased to 71.43%. Moreover, variants of unknown significance that were judged likely pathogenic had a higher percentage in ctDNA exclusively. Across six representative genes (PIK3CA, CTNNB1, AKT1, KRAS, TP53, and MET), the sensitivity and specificity of detection using mutations in tissue sample as a reference were 25 and 96.74%, respectively. Conclusions This study indicates that tissue NGS and ctDNA NGS are complementary rather than exclusive approaches; these data support the idea that ctDNA is a promising tool to interrogate cancer genetics.Keywords
Funding Information
- China Medical University Hospital (DMR107-100)
- Taiwan Ministry of Health and Welfare Clinical Trial Center (MOHW107-TDU-B-212-123004)
This publication has 25 references indexed in Scilit:
- A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinomaOncogene, 2018
- Circulating epithelial cell counts for monitoring the therapeutic outcome of patients with papillary thyroid carcinomaOncotarget, 2017
- Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 PatientsClinical Cancer Research, 2016
- Cell-free DNA as a diagnostic marker for cancer: current insightsOncoTargets and Therapy, 2016
- Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid BiopsyCancer Discovery, 2016
- Exosomes in cancer: small particle, big playerJournal of Hematology & Oncology, 2015
- Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistanceGenome Biology, 2014
- Challenges in circulating tumour cell researchNature Reviews Cancer, 2014
- Liquid Biopsies: Genotyping Circulating Tumor DNAJournal of Clinical Oncology, 2014
- Predicting the Functional, Molecular, and Phenotypic Consequences of Amino Acid Substitutions using Hidden Markov ModelsHuman Mutation, 2012